Last update June 1, 2020
Hepatitis C virus NS5A protein inhibitor.
Used in combination with glecaprevir in the treatment of chronic hepatitis C virus infection.
Oral administration in a daily dose for 8 to 16 weeks.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (lelevated molecular weight and very high plasma protein binding: EMA 2019, AEMPS 2019, Smolders 2019) make it very unlikely its excretion into breast milk in significant amounts
Possible side effects are rare and mild.
We do not have alternatives for Пибрентасвир.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM